Dr. Sharad Jain
MD, DM,
Sr. Consultant Interventional Cardiologist
Appollo Hospitals International Ltd.

Based on the study results, Sacubitril/Valsartan therapy significantly reduced the risk of hospitalization for heart failure and the incidence of renal dysfunction compared to valsartan or individualized medical therapy (IMT) among patients with heart failure with preserved ejection fraction (HFpEF). However, it was associated with an increased risk of symptomatic hypotension and angioedema. Further studies are needed to confirm the long-term benefits and risks of sacubitril/valsartan therapy in this population. Sacubitril/Valsartan may be a reasonable option for patients with HFpEF who are at high risk of hospitalization or renal dysfunction, even if they are considered to be intolerant of the medication. The study found that the new approach of introducing sacubitril-valsartan was well-received by patients, who felt reassured by the information letter and follow-up procedure. ARNI class has sparked considerable excitement in other cardiovascular diseases including hypertension.

Click Here to view the article:

Aha Journals